• In the first quarter ended March 31, 2026, Stoke Therapeutics reported sales of US$6.23 million versus US$158.57 million a year earlier, shifting from net income of US$112.88 million to a net loss of US$50 million and reporting basic and diluted loss per share of US$0.79 from continuing operations.
• Against this backdrop, recent insider activity, including Chief Medical Officer Barry Ticho’s Rule 10b5-1-planned sale of 2,243 shares, leaving him with 36,621 shares, adds an additional lens on management’s positioning as the company advances its RNA-based therapies for severe genetic diseases.
• We’ll now examine how this sharp year-on-year swing from profit to loss in the latest quarter affects Stoke Therapeutics’ existing investment narrative.

Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

Stoke Therapeutics Investment Narrative Recap

To own Stoke Therapeutics, you have to believe its RNA medicines for Dravet syndrome and Autosomal Dominant Optic Atrophy can eventually justify years of heavy investment and current losses. The sharp swing from a US$112.88 million profit to a US$50 million loss in Q1 2026 heightens near term focus on cash burn, but does not directly change the key clinical catalyst: the EMPEROR Phase III data that will test zorevunersen’s disease modifying thesis, or the core risk that those results fall short.

The Q1 2026 earnings release is the most relevant recent event here, as it marks a reset in Stoke’s financial profile after 2025’s unusually high US$184.42 million in sales. With only US$6.23 million in Q1 sales and a widening quarterly loss, the company’s ability to fund the EMPEROR Phase III program and early ADOA work without heavier dilution looks more exposed, especially in light of significant insider selling and a relatively new management team.

Yet investors should also be aware that if EMPEROR timelines slip or costs rise materially, Stoke’s funding runway and reliance on new capital could...

Stoke Therapeutics’ narrative projects $81.1 million revenue and $13.2 million earnings by 2028. This implies a 26.7% yearly revenue decline and an earnings decrease of $27.4 million from $40.6 million today.

Uncover how Stoke Therapeutics' forecasts yield a $34.25 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Before this earnings setback, the most optimistic analysts were still assuming revenue could reach about US$63.4 million and earnings about US$10.2 million by 2028, which is far more upbeat than the baseline view and highlights how differently you and other shareholders might weigh the risk that Stoke is only funded into the mid 2028 time frame while EMPEROR and ADOA spending continue to climb.

Explore 4 other fair value estimates on Stoke Therapeutics - why the stock might be worth less than half the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Stoke Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Stoke Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stoke Therapeutics' overall financial health at a glance.

Want Some Alternatives?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 33 companies in the world exploring or producing it. Find the list for free.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.